|Articles|April 7, 2023
Pharma USA 2023: What Medicare Reform Means to Patient Access Network Foundation
Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes that impact Medicare, as well as the Foundation's near-term goals.
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on how the Foundation will address its near- and longer-term goals.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Wegovy HD Injectable Under Accelerated Approval
2
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics
3
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
4
Pharmaceutical Executive Daily: FDA Approves Wegovy HD
5